Oct 8 (Reuters) – Italy's Newron Pharmaceuticals said on Thursday the FDA had outlined safety concerns behind a clinical hold at US sites in a late-stage trial of its experimental schizophrenia drug,
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Two Strategic Pet-Care Deals, Premium Wellness Launches, Capacity Expansion & Bonus Issue Position Company for…
Oct 8 (Reuters) - * STABLE ASSET MANAGEMENT: ANNOUNCED A $100 MILLION SEED INVESTMENT TO…
IMF: SIGNIFICANT PROGRESS WAS MADE DURING MISSION IN CONGO, DISCUSSIONS WILL CONTINUE IN THE NEXT…
VIDEO SHOWS: COMMENTS FROM FIFA PRESIDENT GIANNI INFANTINO AND CAF PRESIDENT PATRICE MOTSEPE DURING PRESENTATION…
Surat (Gujarat) [India], October 8: The Man-Made Textiles Research Association (MANTRA) has completed 49 glorious…
The Canadian dollar weakened against the greenback on Thursday, and the yield on benchmark government…